The Center for Biosimilars® recaps the top stories for the week of September 16, 2019.
Transcript
Hi, I’m Jaime Rosenberg for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of September 16, 2019.
Number 5: Innovator drug maker Roche says that it plans to see substantial erosion of its sales of rituximab, trastuzumab, and bevacizumab products by 2023.
Number 4: The American College of Rheumatology says that a large proportion of patients with rheumatic diseases had difficulty accessing and paying for their therapies in the past year.
Number 3: The Biosimilars Council has issued part 2 of its recent white paper on barriers to biosimilars in the United States; the newly published segment highlights post-market challenges to biosimilar adoption.
Number 2: A recent study says that step therapy in rheumatoid arthritis or psoriatic arthritis can hurt treatment outcomes.
Number 1: The United States Court of Appeals for the Third Circuit sided with Johnson & Johnson, requiring a dispute between the drug maker and Rochester Drug Cooperative to be sent to arbitration.
Finally, last week, our e-newsletter asked whether you think that Europe’s biosimilars market faces challenges to sustainability.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Eye on Pharma: Henlius, Organon Updates; Meitheal Portfolio Expansion; Celltrion Zymfentra Data
November 5th 2024Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous infliximab (Zymfentra) showed monotherapy could be as effective as combination therapy for inflammatory bowel disease.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Enhancing Adoption of Infused Biosimilars for a Sustainable Future
October 30th 2024An IQVIA report highlights challenges to the sustainability of infused biosimilars in the US, citing rebate walls and reimbursement policies, and proposes key solutions to enhance adoption and benefits for all stakeholders.
Competitive Pricing in Biosimilars: How Adalimumab Could Shape the Industry
Published: October 29th 2024 | Updated: October 29th 2024Sophia Humphreys, PharmD, MHA, BCBBS, of Sutter Health notes that although initial adoption of adalimumab biosimilars remained low in 2023, competitive pricing pressures have already benefited patients and the health care sector.